Susan Elaine Bates

USPTO Granted Patents = 12 (Patent Applications = 1)

Average Co-Inventor Count = 4.1

ph-index = 3

Forward Citations = 17(Granted Patents)

Company Filing History:

11 out of 3,435

National Institutes of Health, a Component of the US Dept. of Health & Human Services

where one patent can have more than one assignee

Years Active: 2003-2018

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9937217 - Method of inhibiting ABCG2 and related treatments (2018-04-10),

2. 9314448 - Method of inhibiting ABCG2 and other treatment methods (2016-04-19),

3. 9259452 - Deacetylase inhibitor therapy (2016-02-16),

4. 9114102 - Method of inhibiting ABCG2 and related treatments (2015-08-25),

5. 8957027 - Deacetylase inhibitor therapy (2015-02-17),

6. 8673888 - Depsipeptide for therapy of kidney cancer (2014-03-18),

7. 8470888 - Botryllamides and method of inhibiting PGP in a mammal afflicted with cancer (2013-06-25),

8. 8273797 - Treating renal cancer using 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde (2012-09-25),

9. 7989501 - Treating renal cancer using a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde (2011-08-02),

10. RE40839 - Taxol treatment of cancer (2009-07-06),

11. 7138493 - ATP-binding cassette protein responsible for cytotoxin resistance (2006-11-21),

12. 6521635 - Inhibition of MXR transport by acridine derivatives (2003-02-18),

Title: Innovations and Contributions of Susan Elaine Bates

Introduction

Susan Elaine Bates is a prominent inventor based in Bethesda, MD, with a remarkable portfolio of 12 patents. Her work primarily focuses on enhancing chemotherapeutic treatments for cancer, showcasing her dedication to improving patient outcomes through innovative medical solutions.

Latest Patents

Among her latest patents is a method of inhibiting ABCG2 and related treatments. This patent discloses methods aimed at enhancing the chemotherapeutic treatment of tumor cells, reducing the resistance of cancer cells to chemotherapeutic agents. It also includes a method of inhibiting ABCG2 or MRP1 in mammals afflicted with cancer, as well as a method to increase the bioavailability of an ABCG2 substrate drug. The methods involve administering peliomycin and other compounds to achieve these therapeutic effects. Another significant patent involves similar methodologies for inhibiting ABCG2, Pgp, or MRP1, emphasizing the administration of effective amounts of specific compounds to improve treatment efficacy.

Career Highlights

Susan has made significant contributions during her career, working with esteemed organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and Gelgene Corporation. Her experience in these institutions has allowed her to develop and refine her innovative approaches to cancer treatment.

Collaborations

Throughout her career, Susan has collaborated with notable professionals, including Robert W. Robey and Michael C. Dean. These collaborations have further enriched her research and development efforts in the field of cancer therapeutics.

Conclusion

Susan Elaine Bates stands out as a dedicated inventor whose work has the potential to transform cancer treatment methodologies. Her innovative patents and collaborations reflect her commitment to advancing medical science and improving patient care.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

1 patent pending:

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.